Lipedema: A Painful Fat Disorder Often Mistaken for Obesity or Lymphedema

Table of Contents

1. What Lipedema Is
2. Who Gets It and When It Starts
3. How It Differs From Obesity and Lymphedema
4. Diagnosis, Stages and the Missing Lab Test
5. How Common It Is and Why Estimates Vary
6. What Research Suggests About Causes
7. Compression and Manual Lymphatic Drainage
8. Exercise and Muscle
9. Low-Carbohydrate and Ketogenic Diets
10. Weight-Loss Surgery and Medicines
11. Liposuction: The 2026 Trial and Earlier Studies
12. What Is Not Known
13. Key Research Papers
14. Connections
15. Featured Videos

What Lipedema Is

The word points to fat (lipo) and swelling (edema), but the defining feature is the fat. A 2021 consensus guideline from a United States committee describes increased nodular, fibrous fat on the buttocks, hips and limbs (Herbst 2021). Reviews describe fat that typically spares the hands, feet and trunk, a sharp line where the leg fat stops at the ankle (the "cuff sign"), and a marked mismatch between a narrower waist and much wider hips (Buso 2019).

Pain is the feature that most separates it from simple fat gain. In a Dutch survey recruited through a patient association, 88.3% reported pain and 85.9% easy bruising (Romeijn 2018). At a Swiss referral hospital, 87.9% of 381 women had pain (Luta 2025). In a Swedish national survey of 245 women, moderate and severe leg heaviness, pain, numbness, cold skin, easy bruising and sleep problems occurred at every stage (Falck 2022). Reviews add that swelling and pain worsen in warm weather and with exercise, and that raising the legs does not relieve them (Buso 2019).

The burden reaches beyond the legs. A German comparison of 39 women with matched controls found lower overall health ratings, more depression, more pain and more pain-related disability, and pain severity tracked with depressive symptoms (Kempa 2024). The Dutch survey measured quality of life at 59.3 against a Dutch female average of 74.9 (Romeijn 2018). A 2025 review also lists an association with blood clots (Cifarelli 2025).

Back to Table of Contents

Who Gets It and When It Starts

Nearly everyone studied is a woman. A family-tree study called it a condition almost exclusively affecting females that usually appears at puberty (Child 2010). In the Swiss cohort, symptoms often began in adolescence (62.2%) and 49.9% reported a family history (Luta 2025). In the Swedish survey, about 70% of the women dated their onset to before age 30, yet only three (1.6%) had been diagnosed before that age (Falck 2022).

The guideline lists the times it develops or worsens: puberty, pregnancy and menopause, which it describes as times of hormone, weight and shape change (Herbst 2021). A review notes that women report rapid growth with stress, surgery or hormonal change (Buck 2016). These timing statements come mainly from patient histories and expert opinion. The papers read for this page give no reliable percentage for how many women worsen at pregnancy or at menopause.

A 2025 narrative review goes further and proposes menopause as a "turning point" driven by a shift in estrogen receptors and by estrogen made inside the fat tissue (Pinto da Costa Viana 2025). That is a proposed model built from earlier research, not a study that followed women through menopause.

Age and weight track with severity in cross-sectional data. In the Swiss cohort, more advanced stages went with older age and higher body mass index, which the authors read as possible progression needing confirmation in studies that follow people over time (Luta 2025). See Menopause for the wider hormonal background.

Back to Table of Contents

How It Differs From Obesity and Lymphedema

The confusion is costly. In the Dutch survey, the average time from first symptoms to diagnosis was 18 years, after a mean of 2.8 doctors (Romeijn 2018). A systematic review states that misdiagnosis as obesity or lymphedema delays care and increases illness (Vazirnia 2026). The overlap is real, because a woman can have lipedema and obesity, or lipedema and lymphedema, at once.

Compared With Obesity

• Where the fat sits. Women with obesity and lipedema had about 23% more leg fat than women matched for age, body mass index and total fat (Cifarelli 2025, Diabetes).
• Touch and bruising. A comparison table in one review lists tenderness to pressure and easy bruising as strongly present in lipedema and absent in obesity (Buso 2019).
• Metabolism. The same matched study measured about 48% greater insulin sensitivity. Among 106 liposuction patients with a median body mass index of 31.6, diabetes was 5% and abnormal blood fats 7% (Ghods 2020). In 1,001 Spanish women from patient associations, the odds of diabetes (0.36) and high blood pressure (0.38) were lower than in the general female population (Vaquero-Ramiro 2026). The picture is not uniform: an Italian study of 360 women found altered glucose metabolism in 34%, rising with stage (Patton 2024).
• Response to weight loss. This one is disputed; see the section on diets. A 2019 review says weight loss has minimal effect on the abnormal fat distribution (Buso 2019), while a 2025 study measured leg fat falling in step with abdominal fat (Cifarelli 2025, Diabetes).
• Inflammation in the blood. In 229 women, C-reactive protein and the sedimentation rate were higher in lipedema and in obesity than in normal-weight women, with no significant difference between lipedema and obesity (Şahingöz Bakırcı 2026). So these tests do not separate the two.

Compared With Lymphedema

The lymphedema page covers that condition in full. What matters here is how the lymph system itself behaves in lipedema:

• The lymph system is mostly not the primary failure. A 1996 study of 10 patients found lymph impairment in most, but never at the low levels seen in true lymphedema (Harwood 1996). A 2026 systematic review of seven studies found normal lymph-scan results in 61.4% of 311 women with lipedema, with twisted lymph vessels the most common abnormality and backflow into the skin in only 3.8%. The authors read this as lymph overload, not outright failure, and noted the studies were too different to pool (Mortada 2026).
• Feet and hands. Lipedema fat usually stops short of them (Buso 2019).
• Swelling on pressing. In a French vein clinic, none of the 36 women with lipedema had pitting (a dent left by a pressing finger) (Rastel 2023). The United States guideline, however, says swelling in lipedema can be pitting or non-pitting (Herbst 2021).
• The two can merge. Secondary lymphedema appeared in 11.8% in the lymph-scan review (Mortada 2026). In 258 Brazilian women with lipedema, leg lymphedema differed significantly between those with a body mass index under 30 and those above it (Pereira de Godoy 2020). Some classifications call this combination stage 4, or lipo-lymphedema, with swollen feet (Buso 2019). The guideline adds that secondary lymphedema often occurs without a positive Stemmer sign, the skin-fold test described on the lymphedema page (Herbst 2021).

Vein disease is the other frequent companion. Chronic venous disease was found in 86.2% of the Swiss cohort (Luta 2025), and the Spanish survey found the odds of venous insufficiency about five times those of the general female population (odds ratio 5.05) (Vaquero-Ramiro 2026). See Varicose Veins.

Back to Table of Contents

Diagnosis, Stages and the Missing Lab Test

No blood test or tissue test is established. A 2020 review states that no specific biomarker has been found, that diagnosis rests on clinical grounds alone, and that other tests serve only to rule out competing diagnoses (Kruppa 2020). A tissue study agrees that no microscopic or molecular hallmark clearly diagnoses it (Felmerer 2020, J Surg Res). A 2025 review lists the absence of a definitive test as a main reason the diagnosis stays subjective (Cifarelli 2025).

A 2016 review traces the clinical criteria to 1951 (Buck 2016). Two recent documents try to tighten this. The German S2k guideline contains 60 recommendations on diagnosis, treatment, psychosocial factors and self-management (Faerber 2024). A 2024 research framework separates five agreed characteristics from five disputed ones, so that future studies can count the same people (Keith 2024).

Stages and Types

• Stage 1: smooth skin over a pebble-like feel beneath it (Herbst 2021).
• Stage 2: more tissue and dimpled skin (Herbst 2021).
• Stage 3: large nodules and overhanging lobes of tissue (Herbst 2021).
• Stage 4: used by some authors for lipedema with added lymphedema (Buso 2019).

Types describe location instead of severity: type I around the hips and buttocks, type II to the knees, type III to the ankles, type IV the arms, type V the lower legs (Herbst 2021). In the Swiss cohort, type III (48.3%) and type IV (30.2%) were most common, and 26.6% were stage 1, 44.5% stage 2 and 28.9% stages 3 to 4 (Luta 2025).

Staging is itself unsettled. A 2025 study proposes in-between stages 1.5 and 2.5 (Al-Ghadban 2025), and a 2026 paper repeatedly calls the stages "obsolete" and found that they did not influence pain or pain relief (Mendoza 2026). An Italian study, by contrast, found pain scores rising with stage (Patton 2024).

Tests Under Study

• Ultrasound. A study of 89 women at one institution derived cutoff values for the thickness of skin and fat, naming the shin as the leading measurement site (Amato 2021). These come from one center and rest on a clinical diagnosis as the reference.
• Sodium scanning. Magnetic resonance imaging found more sodium in the skin (14.9 versus 11.9 mmol/L) and fat (11.9 versus 9.4 mmol/L) of the calf in 10 women with lipedema than in 11 matched controls (Crescenzi 2018).
• Uric acid. A blood-chemistry screen flagged uric acid, measured at 5.05 mg/dL in lipedema, 5.4 in lymphedema and 4.6 in overweight controls. A related ratio lost significance after adjusting for kidney function (Alkhalfan 2025).

Back to Table of Contents

How Common It Is and Why Estimates Vary

A 2022 paper gives the estimated range in Europe as 0.06% to 39% (Amato 2022, Brazil). A range that wide says more about how lipedema gets counted than about how many women have it. A 2019 review describes the data as scarce and conflicting (Buso 2019).

• 39%: a German study of 62 professional women, counting all stages; moderate to severe disease was up to 9.7% (described in Buso 2019).
• 12.3%: an online symptom questionnaire answered by 253 Brazilian women, plus or minus 4 points. This measures a high probability of the diagnosis, not an examination (Amato 2022, Brazil).
• About 11%: a figure stated in reviews, sometimes as "believed to affect" or "nearly 1 in 9" adult women (Buck 2016; Katzer 2021).
• About 10%: stated in reviews as an estimate for women overall (Kruppa 2020; Cifarelli 2025).
• 6% to 11%: described as an indirect estimate, derived from lipedema misdiagnosed as lymphedema (Cifarelli 2025).
• 7.7%: of 464 women at one French vein clinic, a group already selected for leg symptoms (Rastel 2023).

The causes of the spread are stated openly in the literature. There is no objective test. There has been no single case definition for researchers to use (Keith 2024). Many clinicians do not recognize the condition, and it can be recorded as obesity or lymphedema. The 2025 review adds that the World Health Organization lists lipedema as a distinct disease in its newest classification, while the United States was still using the older coding system, which limits counting from records (Cifarelli 2025). Who gets asked matters too: professional women, vein-clinic patients and online respondents are different groups. None of the studies read for this page counted cases by physical examination in a random sample of a general population, and the 2025 review states that the true figure remains unknown.

Back to Table of Contents

What Research Suggests About Causes

The cause is unknown (Kruppa 2020). The leading ideas are genetic, hormonal and vascular, possibly in combination (Buso 2019; Cifarelli 2025). Most tissue studies below involve a few dozen women or fewer.

Inheritance

Family trees suggested a dominant pattern limited to females (Child 2010). In one family with three affected members, gene sequencing found a variant in AKR1C1, a gene for an enzyme that inactivates progesterone. Computer modeling suggested partial loss of function, and the authors called it the first candidate gene (Michelini 2020). That is one family, and no single causative gene has been confirmed (Cifarelli 2025).

Hormones

Estrogen is suspected because of the sex pattern and the timing. A 2021 review proposes altered estrogen receptor balance in fat cells and more estrogen produced locally by those cells (Katzer 2021). This is a reasoned hypothesis, assembled from research on fat tissue generally.

Changes in the Fat Tissue

• Biopsies from 30 women with lipedema and 19 controls found enlarged fat cells and more macrophages (a type of immune cell) even in women without obesity, with new blood-vessel growth in 30% of the lipedema samples and in no controls (Al-Ghadban 2019).
• Comparison of 10 women with lipedema and 11 matched controls found more scar-like fibrosis, larger fat cells and more macrophages, with no change in T cells (Felmerer 2020, J Surg Res).
• Biopsies from 32 patients and 14 controls found fat-cell size rising with stage, more collagen in the thighs but not the lower abdomen, and a macrophage pattern differing from primary obesity (Kruppa 2023).
• A study of 11 women and 10 matched controls found higher blood levels of a lymph-vessel growth signal but no visible change in the lymph vessels themselves, and the authors concluded no apparent lymphatic anomaly underlies lipedema (Felmerer 2020, Sci Rep).

Nerves and Pain

In 27 women with lipedema and 23 controls, the skin of those at stages 2 to 3 was oversensitive to light pressure on the calf and thigh. Skin biopsies showed fewer nerve cell bodies and, at stage 3, higher levels of two pain-related signals (Chakraborty 2022). This supports nerve involvement in the pain without settling why it starts.

Connective Tissue and Other Associations

The United States guideline frames lipedema as a loose connective tissue disease (Herbst 2021). An online survey found 44% of women with lipedema reporting loose joints and 60% recalling them in childhood (Fiengo 2025). These are self-reports, not diagnoses of hypermobile Ehlers-Danlos syndrome. In clinic data, the Italian study found more autoimmune thyroid disease and polycystic ovary syndrome than in the general population (Patton 2024). Among 95 women, 61.1% carried a gene type linked to celiac disease, higher than in the general population (Amato 2023). That is an association in patients seeking care, and the authors state that research on removing gluten is still needed.

Back to Table of Contents

Compression and Manual Lymphatic Drainage

Complex decongestive therapy combines compression, manual lymphatic drainage, skin care and exercise. A 2020 review says treatment generally consists of it and that the state of the evidence on treatment is poor (Kruppa 2020). The 2026 Lancet paper describes it as the standard of care, offering limited symptom relief (Podda 2026). A 2026 review of physical therapy says there is still no consensus on evidence-based approaches (Modena 2026).

What the Trials Measured

• Severe lipedema, 33 women, 6 weeks. All did the exercise program, adding complex decongestive therapy, a pneumatic pump or nothing further. All groups improved; the group with complex decongestive therapy did best on limb volume, pain and physical function (Atan 2021).
• Bruising, 38 women, 5 days. Complex decongestive therapy reduced tiny skin hemorrhages and capillary fragility, while moisturizer alone did not (Szolnoky 2008, Lymphology 41:161).
• Adding a pump, 24 women, 5 days. Both groups lost leg volume, and the pump was safe but added no extra volume reduction (Szolnoky 2008, Lymphology 41:40).
• Adding a pump to garments, women with lipedema and secondary lymphedema. An industry-sponsored proof-of-principle trial found leg circumference improved in both groups, more with the pump, and better pain scores in the pump group (Wright 2023).
• Pain after pump use, 90 women already on drainage and garments. Pain fell from a mean of 6.5 to 3.8 after 10 to 14 days. There was no control group, and the pump trial was provided by a device company (Mendoza 2026).
• Drainage plus vibration, 30 women. Six sessions of drainage plus low-frequency vibration beat six sessions of drainage alone on limb size and quality of life (Schneider 2020). This compares two active options and does not measure drainage against nothing.
• Multimodal physical therapy, 5 women. Nine visits in 6 weeks reduced pain and skin and fat sodium (Donahue 2022). With five participants, this is a proof of principle.
• Fluid, 22 women, 1 month. Fluid inside and outside cells fell by bioimpedance measurement (Esmer 2024). The authors infer slower progression, but the study was too short and had no comparison group to test that.

Limits

Most of these trials are small, brief and unable to hide the treatment from participants, whose pain reports are the main outcome. None here shows fat being removed or the disease stopped. The page on manual lymphatic drainage covers how the technique works.

The United States guideline lists compression garments as a standard treatment for women with signs of lymph impairment. It also states that in lipedema, garments often cause pain, and that they are contraindicated in severe peripheral arterial disease (Herbst 2021). Conservative care in the Lancet trial shows the other side of the picture: after up to 7 months of it before randomization, continued conservative therapy brought a 2-point pain drop to 8% of women over the next year (Podda 2026).

Back to Table of Contents

Exercise and Muscle

A 2024 Italian consensus statement says that although lipedema is defined as resistant to diet and exercise, exercise has a key role in managing it, naming water exercise and strength training for symptoms and quality of life. It also states that standard exercise guidelines are lacking (Annunziata 2024). A systematic review links water exercise with reduced pain and swelling, graded 2A to 2B on its scale, drawn mostly from observational work (Vazirnia 2026).

Direct trial evidence of exercise alone is thin. In the 33-woman trial above, exercise was given to every group, including the comparison, and those participants also improved, but no group went without exercise (Atan 2021). Reviews note that symptoms can worsen during exercise (Buso 2019), so the type and dose studied matter.

Muscle is an open question. Among 48 women, 33.3% met criteria for sarcopenia (low muscle mass and function), 14.6% severe, with weaker grip and slower walking at higher stages (Ozbek 2026). A different study measured skeletal muscle mass increasing across stages, along with fat (Al-Ghadban 2025). Those two findings used different measurements and do not settle whether strength falls because of disease, pain or inactivity.

Back to Table of Contents

Low-Carbohydrate and Ketogenic Diets

A 2022 pilot describes clinical experience suggesting that low-carbohydrate, high-fat eating might help with weight and symptoms (Sørlie 2022). A systematic review grades ketogenic and Rare Adipose Disorders diets at 2A to 2B for reduced pain and swelling (Vazirnia 2026). The trial record is recent and short.

• Randomized trial, 70 women with lipedema and obesity, 8 weeks. Both diets gave 1,200 kcal a day. The low-carbohydrate group lost 2.8 kg more and had 1.1 points more reduction in current pain. Pain change did not track weight loss (Lundanes 2024).
• Same trial, blood markers. Three inflammation markers fell in the low-carbohydrate group only, but the difference between groups was not significant, and marker changes did not track pain. The authors concluded that inflammation does not seem to explain the pain relief (Lundanes 2025).
• Pilot, 9 women, no control group. Seven weeks of a low-carbohydrate, high-fat diet without calorie cutting brought 4.6 kg of weight loss and a 2.3 cm pain drop on a visual scale. After 6 weeks on a standard Nordic diet, weight stayed off but pain returned to its starting level (Sørlie 2022). One reading is that the pain effect depends on staying on the diet, though nine women can only hint at that.
• Two diets, 91 women, 16 weeks. Low-carbohydrate, high-fat eating beat a moderate diet for weight (8.2 versus 2.1 kg lost) and hips (7.4 versus 2.5 cm lost). The abstract does not describe the groups as randomized and says the pain data were "not shown" (Jeziorek 2022).
• Seven months, 113 enrolled, 52 finished. Weight loss was similar with or without lipedema (10.8 and 11.9 kg). Pain among those with lipedema fell from 4.6 to 3.0 (Jeziorek 2023). More than half of those enrolled did not complete it.
• Modified Mediterranean diet, 14 women with lipedema and 15 controls, 4 weeks. Women with lipedema lost fat in the arms and legs and reported easier daily activity (Di Renzo 2021).

Whether diet reaches lipedema fat at all is the key dispute. The common teaching is that it does not (Sørlie 2022 and Buso 2019 describe this view). A 2025 study in the journal Diabetes tested it: in women with obesity and lipedema, about 9% diet-induced weight loss improved insulin sensitivity and cut abdominal and leg fat by similar proportions. Tissue markers of inflammation and fibrosis did not change. The authors called weight loss the first-line therapy for women with obesity and lipedema (Cifarelli 2025, Diabetes). These results apply to women who also have obesity, and they say nothing about women of normal weight. See Ketogenic Diet and Obesity.

Long-term results are missing: the longest diet study here ran 7 months with heavy dropout, and none of these studies tested whether a diet prevents progression.

Back to Table of Contents

Weight-Loss Surgery and Medicines

A 2026 systematic review of bariatric surgery found only seven studies and 51 patients, five of them case reports. Total weight loss averaged 33.9%. One study reported reduced thigh volume, while the others described persistent or worse lower-body disproportion and no improvement in pain. The authors concluded that surgery reduces weight but does not consistently improve core symptoms (Pajaziti 2026). That one study followed 31 women, whose adjusted thigh volume fell 33.4% and then 30.4%, close to the 37.0% and 34.7% in controls with lymphedema of the lower leg (Fink 2021).

For glucagon-like peptide-1 receptor agonist medicines, including the dual-action drug tirzepatide, this page found patient-reported data. In an online survey with 2,719 analyzed respondents, about 55% were current users, and they rated health higher and symptoms lower than never-users (Srinivasan 2026). People who feel better may be likelier to continue a medicine and answer a survey, so this cannot establish that the drug caused the difference. The authors call for further investigation.

Back to Table of Contents

Liposuction: The 2026 Trial and Earlier Studies

The Randomized Trial

The trial ran at 11 German centers and was paid for by Germany's Federal Joint Committee. Of 1,973 patients screened, 410 with stage I to III disease and leg pain of at least 4 out of 10 were randomized after up to 7 months of conservative therapy: 278 to liposuction and 132 to continued conservative therapy (Podda 2026).

• Pain at 12 months. 190 of 278 (68%) reached a drop of at least 2 points on the 10-point scale, against 10 of 132 (8%) with conservative therapy. The odds ratio was 26.2.
• Quality of life. Secondary measures improved more with liposuction.
• Harms. Adverse events occurred in 124 of 265 (47%) of those undergoing liposuction, and serious ones in 20 of 265 (8%). With conservative therapy the figures were 30 of 145 (21%) and 5 of 145 (3%).

The trial's limits are stated in its design. Women knew which treatment they had received, and the main outcome was their own pain report; patches on the legs hid it only from the assessor, and there was no sham operation. Everyone had already been through conservative therapy, so the 8% figure describes further change on continued care, not first-time response. Results extend to 12 months, with 36-month follow-up ongoing. The authors conclude it was superior for pain and quality of life but carried a higher rate of serious adverse events, and they describe it as having the potential to be a promising option.

Before the Trial

• A 2026 review of 25 studies and 2,373 patients found reduced pain and better mobility and quality of life, with a mean of 3,077 mL removed per session and 6,111 mL per course. It called complications uncommon, listing bruise-like blood collections, swelling, anemia, deep vein thrombosis and rare methemoglobinemia (a blood oxygen-carrying problem). Its evidence level is 4, and only 2 of the 15 studies reporting tumescent fluid fully described what was in it (Vengoechea 2026).
• 85 patients followed for an average of 8 years, largely by mailed questionnaire, kept their improvement in pain, bruising and movement and needed less conservative treatment (Baumgartner 2016).
• 25 patients and 72 procedures showed improvements holding at 37 months, with better results at earlier stages (Dadras 2017). A review notes that consistent criteria for timing or patient selection are lacking (Buso 2019).
• A 2020 review reported only rare complications in observational studies (Kruppa 2020). The trial's figures are clearly higher. The two are not measured the same way, and a trial of this kind records events more systematically than most clinic series.

A 2017 consensus conference called lymph-sparing liposuction the only effective treatment and titled its report around preventing progression (Sandhofer 2020). The 12-month trial did not test whether liposuction changes the long-term course of the disease. On cost, a 2020 review noted that German statutory insurers did not then regularly cover it, pending stronger studies (Kruppa 2020).

Back to Table of Contents

What Is Not Known

• The cause. No confirmed gene, no proven hormonal mechanism, and no agreement on whether lymph and vessel changes come first or follow later.
• How many women have it. Reported numbers run from under 1% to 39%, and a shared case definition has only recently been proposed.
• The natural course. Reviews call it progressive (Vazirnia 2026), but the Swiss data compare women at different stages at one point in time, and those authors say prospective studies are needed for confirmation (Luta 2025).
• A test. Among the studies read here, no biomarker or imaging cutoff has been shown to work across centers.
• What pregnancy and menopause do, in numbers. The timing rests on patient history and proposed models.
• Lasting effects of diet. Trials ran for weeks to months, and the one pilot that stopped the diet saw pain return.
• What conservative care adds by itself. Few trials have an untreated comparison, and most are small.
• Whether liposuction changes the course. Long-term randomized results are still pending.
• Medicines. The papers read here offer survey data on weight-loss medicines, and no randomized trial for lipedema.
• Women with normal weight. Several of the diet studies enrolled only women with obesity, so their results may not carry over.

Several papers state that no curative treatment exists (Cifarelli 2025; Donahue 2022; Esmer 2024). Decisions about treatment belong with a clinician who knows the condition.

Back to Table of Contents

Key Research Papers

1. Al-Ghadban S, Cromer W, Allen M, Ussery C, Badowski M, Harris D, Herbst KL. Dilated Blood and Lymphatic Microvessels, Angiogenesis, Increased Macrophages, and Adipocyte Hypertrophy in Lipedema Thigh Skin and Fat Tissue. J Obes. 2019;2019:8747461. PubMed PMID: 30949365
2. Al-Ghadban S, Evancio JV, Alfiscar PEF, Herbst KL. New Characterization of Lipedema Stages: Focus on Pain, Water, Fat and Skeletal Muscle. Life (Basel). 2025;15(9):1397. PubMed PMID: 41010339
3. Alkhalfan F, Sangwan N, Aggarwal A, Scalise A, Alemán JO, Rajasekar B, Joseph D, Peterson K, Hamer A, Ali M, Bartholomew JR, Cameron SJ. Exploring uric acid as a biomarker in lipedema and lymphedema: A metabolomics study with prospective validation. Obes Med. 2025;55:100618. PubMed PMID: 42016523
4. Amato AC, Amato LL, Benitti D, Amato JL. Assessing the Prevalence of HLA-DQ2 and HLA-DQ8 in Lipedema Patients and the Potential Benefits of a Gluten-Free Diet. Cureus. 2023;15(7):e41594. PubMed PMID: 37431427
5. Amato ACM, Amato FCM, Amato JLS, Benitti DA. Lipedema prevalence and risk factors in Brazil. J Vasc Bras. 2022;21:e20210198. PubMed PMID: 35677743
6. Amato ACM, Saucedo DZ, Santos KDS, Benitti DA. Ultrasound criteria for lipedema diagnosis. Phlebology. 2021;36(8):651-658. PubMed PMID: 33853452
7. Annunziata G, Paoli A, Manzi V, Camajani E, Laterza F, Verde L, Capó X, Padua E, Bianco A, Carraro A, Di Baldassarre A, Guidetti L, Marcora SM, Orrù S, Tessitore A, Di Mitri R, Auletta L, Piantadosi A, Bellisi M, Palmeri E, Savastano S, Colao A, Caprio M, Muscogiuri G, Barrea L. The Role of Physical Exercise as a Therapeutic Tool to Improve Lipedema: A Consensus Statement from the Italian Society of Motor and Sports Sciences (Società Italiana di Scienze Motorie e Sportive, SISMeS) and the Italian Society of Phlebology (Società Italiana di Flebologia, SIF). Curr Obes Rep. 2024;13(4):667-679. PubMed PMID: 38958868
8. Atan T, Bahar-Özdemir Y. The Effects of Complete Decongestive Therapy or Intermittent Pneumatic Compression Therapy or Exercise Only in the Treatment of Severe Lipedema: A Randomized Controlled Trial. Lymphat Res Biol. 2021;19(1):86-95. PubMed PMID: 33297826
9. Baumgartner A, Hueppe M, Schmeller W. Long-term benefit of liposuction in patients with lipoedema: a follow-up study after an average of 4 and 8 years. Br J Dermatol. 2016;174(5):1061-7. PubMed PMID: 26574236
10. Buck DW, Herbst KL. Lipedema: A Relatively Common Disease with Extremely Common Misconceptions. Plast Reconstr Surg Glob Open. 2016;4(9):e1043. PubMed PMID: 27757353
11. Buso G, Depairon M, Tomson D, Raffoul W, Vettor R, Mazzolai L. Lipedema: A Call to Action! Obesity (Silver Spring). 2019;27(10):1567-1576. PubMed PMID: 31544340
12. Chakraborty A, Crescenzi R, Usman TA, Reyna AJ, Garza ME, Al-Ghadban S, Herbst KL, Donahue PMC, Rutkowski JM. Indications of Peripheral Pain, Dermal Hypersensitivity, and Neurogenic Inflammation in Patients with Lipedema. Int J Mol Sci. 2022;23(18):10313. PubMed PMID: 36142221
13. Child AH, Gordon KD, Sharpe P, Brice G, Ostergaard P, Jeffery S, Mortimer PS. Lipedema: an inherited condition. Am J Med Genet A. 2010;152A(4):970-6. PubMed PMID: 20358611
14. Cifarelli V. Lipedema: Progress, Challenges, and the Road Ahead. Obes Rev. 2025;26(10):e13953. PubMed PMID: 40425048
15. Cifarelli V, Smith GI, Gonzalez-Nieves S, Samovski D, Palacios HH, Yoshino J, Stein RI, Fuchs A, Wright TF, Klein S. Adipose Tissue Biology and Effect of Weight Loss in Women With Lipedema. Diabetes. 2025;74(3):308-319. PubMed PMID: 39652636
16. Crescenzi R, Marton A, Donahue PMC, Mahany HB, Lants SK, Wang P, Beckman JA, Donahue MJ, Titze J. Tissue Sodium Content is Elevated in the Skin and Subcutaneous Adipose Tissue in Women with Lipedema. Obesity (Silver Spring). 2018;26(2):310-317. PubMed PMID: 29280322
17. Dadras M, Mallinger PJ, Corterier CC, Theodosiadi S, Ghods M. Liposuction in the Treatment of Lipedema: A Longitudinal Study. Arch Plast Surg. 2017;44(4):324-331. PubMed PMID: 28728329
18. Di Renzo L, Cinelli G, Romano L, Zomparelli S, Lou De Santis G, Nocerino P, Bigioni G, Arsini L, Cenname G, Pujia A, Chiricolo G, De Lorenzo A. Potential Effects of a Modified Mediterranean Diet on Body Composition in Lipoedema. Nutrients. 2021;13(2):358. PubMed PMID: 33504026
19. Donahue PMC, Crescenzi R, Petersen KJ, Garza M, Patel N, Lee C, Chen SC, Donahue MJ. Physical Therapy in Women with Early Stage Lipedema: Potential Impact of Multimodal Manual Therapy, Compression, Exercise, and Education Interventions. Lymphat Res Biol. 2022;20(4):382-390. PubMed PMID: 34748408
20. Esmer M, Schingale FJ. Can Physical Therapy Techniques Slow Down the Progression of Lipedema? Lymphat Res Biol. 2024;22(6):267-270. PubMed PMID: 39381855
21. Faerber G, Cornely M, Daubert C, Erbacher G, Fink J, Hirsch T, Mendoza E, Miller A, Rabe E, Rapprich S, Reich-Schupke S, Stücker M, Brenner E. S2k guideline lipedema. J Dtsch Dermatol Ges. 2024;22(9):1303-1315. PubMed PMID: 39188170
22. Falck J, Rolander B, Nygårdh A, Jonasson LL, Mårtensson J. Women with lipoedema: a national survey on their health, health-related quality of life, and sense of coherence. BMC Womens Health. 2022;22(1):457. PubMed PMID: 36401222
23. Felmerer G, Stylianaki A, Hollmén M, Ströbel P, Stepniewski A, Wang A, Frueh FS, Kim BS, Giovanoli P, Lindenblatt N, Gousopoulos E. Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. Sci Rep. 2020;10(1):10947. PubMed PMID: 32616854
24. Felmerer G, Stylianaki A, Hägerling R, Wang A, Ströbel P, Hollmén M, Lindenblatt N, Gousopoulos E. Adipose Tissue Hypertrophy, An Aberrant Biochemical Profile and Distinct Gene Expression in Lipedema. J Surg Res. 2020;253:294-303. PubMed PMID: 32407981
25. Fiengo E, Sbarbati A. Lipedema and Hypermobility Spectrum Disorders Sharing Pathophysiology: A Cross-Sectional Observational Study. J Clin Med. 2025;14(20):7195. PubMed PMID: 41156066
26. Fink JM, Schreiner L, Marjanovic G, Erbacher G, Seifert GJ, Foeldi M, Bertsch T. Leg Volume in Patients with Lipoedema following Bariatric Surgery. Visc Med. 2021;37(3):206-211. PubMed PMID: 34250078
27. Ghods M, Georgiou I, Schmidt J, Kruppa P. Disease progression and comorbidities in lipedema patients: A 10-year retrospective analysis. Dermatol Ther. 2020;33(6):e14534. PubMed PMID: 33184945
28. Harwood CA, Bull RH, Evans J, Mortimer PS. Lymphatic and venous function in lipoedema. Br J Dermatol. 1996;134(1):1-6. PubMed PMID: 8745878
29. Herbst KL, Kahn LA, Iker E, Ehrlich C, Wright T, McHutchison L, Schwartz J, Sleigh M, Donahue PM, Lisson KH, Faris T, Miller J, Lontok E, Schwartz MS, Dean SM, Bartholomew JR, Armour P, Correa-Perez M, Pennings N, Wallace EL, Larson E. Standard of care for lipedema in the United States. Phlebology. 2021;36(10):779-796. PubMed PMID: 34049453
30. Jeziorek M, Chachaj A, Sowicz M, Adaszyńska A, Truszyński A, Putek J, Kujawa K, Szuba A. The Benefits of Low-Carbohydrate, High-Fat (LCHF) Diet on Body Composition, Leg Volume, and Pain in Women with Lipedema. J Obes. 2023;2023:5826630. PubMed PMID: 38026822
31. Jeziorek M, Szuba A, Kujawa K, Regulska-Ilow B. The Effect of a Low-Carbohydrate, High-Fat Diet versus Moderate-Carbohydrate and Fat Diet on Body Composition in Patients with Lipedema. Diabetes Metab Syndr Obes. 2022;15:2545-2561. PubMed PMID: 36035515
32. Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation. Int J Mol Sci. 2021;22(21):11720. PubMed PMID: 34769153
33. Keith L, Seo C, Wahi MM, Huggins S, Carmody M, Faerber G, Forner-Cordero I, Michelini S, Rapprich S, Rockson SG. Proposed Framework for Research Case Definitions of Lipedema. Lymphat Res Biol. 2024;22(2):93-105. PubMed PMID: 38546398
34. Kempa S, Gross M, Oliinyk D, Siegmund A, Müller M, Prantl L, Tews HC. Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls. Life (Basel). 2024;14(3):295. PubMed PMID: 38541622
35. Kruppa P, Georgiou I, Biermann N, Prantl L, Klein-Weigel P, Ghods M. Lipedema-Pathogenesis, Diagnosis, and Treatment Options. Dtsch Arztebl Int. 2020;117(22-23):396-403. PubMed PMID: 32762835
36. Kruppa P, Gohlke S, Łapiński K, Garcia-Carrizo F, Soultoukis GA, Infanger M, Schulz TJ, Ghods M. Lipedema stage affects adipocyte hypertrophy, subcutaneous adipose tissue inflammation and interstitial fibrosis. Front Immunol. 2023;14:1223264. PubMed PMID: 37575263
37. Lundanes J, Nes VF, Aakervik O, Ryan L, Hansson P, Rokstad AM, Martins C, Nymo S. Changes in Cytokines and Fibrotic Growth Factors after Low-Carbohydrate or Low-Fat Low-Energy Diets in Females with Lipedema. Curr Dev Nutr. 2025;9(3):104571. PubMed PMID: 40125475
38. Lundanes J, Sandnes F, Gjeilo KH, Hansson P, Salater S, Martins C, Nymo S. Effect of a low-carbohydrate diet on pain and quality of life in female patients with lipedema: a randomized controlled trial. Obesity (Silver Spring). 2024;32(6):1071-1082. PubMed PMID: 38627016
39. Luta X, Buso G, Porceddu E, Psychogyiou R, Keller S, Mazzolai L. Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre. PLoS One. 2025;20(3):e0319099. PubMed PMID: 40111978
40. Mendoza E. Effects of intermittent pneumatic compression on pain in women with lipedema. Phlebology. 2026:2683555261503900. PubMed PMID: 42960549
41. Michelini S, Chiurazzi P, Marino V, Dell'Orco D, Manara E, Baglivo M, Fiorentino A, Maltese PE, Pinelli M, Herbst KL, Dautaj A, Bertelli M. Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema. Int J Mol Sci. 2020;21(17):6264. PubMed PMID: 32872468
42. Modena DAO, Baiocchi JMT, Guirro ECO. The role of physical therapy in the treatment of lipedema: an integrative review of therapeutic strategies and the current clinical landscape. J Vasc Bras. 2026;25:e20250196. PubMed PMID: 42564638
43. Mortada H, Alsaif MA, AlJohani A, Altuwaijri AM, Alshomer F. Lymphoscintigraphic Findings in Patients With Lipedema: A Systematic Review. Plast Reconstr Surg Glob Open. 2026;14(8):e8015. PubMed PMID: 42578114
44. Ozbek IC, Kuculmez O, Dundar Ahi E. Prevalence of sarcopenia and its functional correlates in women with lower-extremity lipedema: A cross-sectional observational study. Phlebology. 2026:2683555261451570. PubMed PMID: 42102393
45. Pajaziti Q, Geropoulos G, MacVicar E, Colucci N, Lucocq J, Lamb PJ, Robertson AG. Lipoedema and Bariatric and Metabolic Surgery: A Systematic Review. Clin Obes. 2026;16(1):e70062. PubMed PMID: 41432544
46. Patton L, Ricolfi L, Bortolon M, Gabriele G, Zolesio P, Cione E, Cannataro R. Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History. Int J Mol Sci. 2024;25(3):1599. PubMed PMID: 38338878
47. Pereira de Godoy LM, Pereira de Godoy HJ, Pereira de Godoy Capeletto P, Guerreiro Godoy MF, Pereira de Godoy JM. Lipedema and the Evolution to Lymphedema With the Progression of Obesity. Cureus. 2020;12(12):e11854. PubMed PMID: 33282608
48. Pinto da Costa Viana D, Caseri Câmara L, Borges Palau R. Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model. Int J Mol Sci. 2025;26(15):7074. PubMed PMID: 40806207
49. Podda M, Schmidt J, Cornely ME, Steinmetz MI, Rajewski D, Busch KH, Taufig Z, Ghods M, Kovacs M, Schmid S, Kraus D, Hellmich M, Müller W, Schiller P, Cornely OA. Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomised controlled clinical trial. Lancet. 2026;408(10558):910-923. PubMed PMID: 42692034
50. Rastel D, Urbinelli R. Frequency of lipoedema in patients consulting a vein clinic for mild to moderate superficial venous disorder with symptoms: A retrospective analysis. J Med Vasc. 2023;48(2):55-61. PubMed PMID: 37422328
51. Romeijn JRM, de Rooij MJM, Janssen L, Martens H. Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey. Dermatol Ther (Heidelb). 2018;8(2):303-311. PubMed PMID: 29748843
52. Sandhofer M, Hanke CW, Habbema L, Podda M, Rapprich S, Schmeller W, Herbst K, Anderhuber F, Pilsl U, Sattler G, Sandhofer M, Moosbauer W, Sattler S, Schauer P, Faulhaber J, Maier S, Barsch M, Mindt S, Halk AB. Prevention of Progression of Lipedema With Liposuction Using Tumescent Local Anesthesia: Results of an International Consensus Conference. Dermatol Surg. 2020;46(2):220-228. PubMed PMID: 31356433
53. Schneider R. Low-frequency vibrotherapy considerably improves the effectiveness of manual lymphatic drainage (MLD) in patients with lipedema: A two-armed, randomized, controlled pragmatic trial. Physiother Theory Pract. 2020;36(1):63-70. PubMed PMID: 29847188
54. Srinivasan A, Kartt J, Daftuar F, Harmacek LD, Samouhos E, Galia S, Heil S, Clark E, Mascio C, Cochrane JC. GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey. Obes Pillars. 2026;19:100316. PubMed PMID: 42656629
55. Szolnoky G, Borsos B, Bársony K, Balogh M, Kemény L. Complete decongestive physiotherapy with and without pneumatic compression for treatment of lipedema: a pilot study. Lymphology. 2008;41(1):40-4. PubMed PMID: 18581957
56. Szolnoky G, Nagy N, Kovács RK, Dósa-Rácz E, Szabó A, Bársony K, Balogh M, Kemény L. Complex decongestive physiotherapy decreases capillary fragility in lipedema. Lymphology. 2008;41(4):161-6. PubMed PMID: 19306662
57. Sørlie V, De Soysa AK, Hyldmo ÅA, Retterstøl K, Martins C, Nymo S. Effect of a ketogenic diet on pain and quality of life in patients with lipedema: The LIPODIET pilot study. Obes Sci Pract. 2022;8(4):483-493. PubMed PMID: 35949278
58. Vaquero-Ramiro E, Puentes-Gutiérrez AB, Morandeira-Rivas A, Millán-Casas L, García-Bascones M. Prevalence of comorbidities associated with lipedema. A comparative study with the general population. Phlebology. 2026:2683555261435120. PubMed PMID: 41886595
59. Vazirnia A, Smart DR, Mohseni Y, Amron DM. Lipedema Diagnosis, Clinical Manifestations, and Therapeutics: A Systematic Review. Int J Dermatol. 2026;65(9):1811-1819. PubMed PMID: 41498193
60. Vengoechea JAA, Gagliardi RC, Martín MIM, Valencia CZ, Triana BM, Limia SB, Figueroa CR, Millán C, Meyer PF. Safety and Efficacy of Surgical Techniques in Treating Lipedema: Systematic Review. Aesthet Surg J Open Forum. 2026;8:ojag039. PubMed PMID: 41884178
61. Wright T, Scarfino CD, O'Malley EM. Effect of pneumatic compression device and stocking use on symptoms and quality of life in women with lipedema: A proof-in-principle randomized trial. Phlebology. 2023;38(1):51-61. PubMed PMID: 36519532
62. Şahingöz Bakırcı E, Demir Karakılıç G. Inflammatory Profile of Lipedema: A Comparative Evaluation with Obese and Normal-Weight Women. Horm Metab Res. 2026;58(8):291-298. PubMed PMID: 42379186

PubMed Topic Searches

1. Lipedema reviews
2. Lipoedema and liposuction
3. Lipedema and ketogenic or low-carbohydrate diet
4. Lipedema, compression and manual lymphatic drainage
5. Lipedema prevalence

Back to Table of Contents

Connections

• Hematology
• Lymphedema — the condition lipedema is most often mistaken for, with its treatment program in full
• Manual Lymphatic Drainage — how the technique works and what it does and does not do
• Obesity — the other common misdiagnosis, and a frequent companion condition
• Ketogenic Diet — the general research on the diet studied here for lipedema pain
• Varicose Veins — vein disease found in many women with lipedema
• Polycystic Ovary Syndrome — found more often in one large lipedema cohort
• Menopause — one of the hormonal transitions linked to worsening

Back to Table of Contents

Featured Videos